Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Regeneron Pharmaceuticals Sets Q4 and Full Year 2024 Earnings Release for February 4

January 08, 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will release its financial and operating results for the fourth quarter and full year 2024 on February 4, 2025. Along with the earnings release, the company will also host a conference call and webcast to discuss the results.

Regeneron, a leading biotechnology company that focuses on the discovery, development, and commercialization of innovative medicines, has been making significant strides in the pharmaceutical industry. With a strong pipeline of potential drugs and successful partnerships, the company has positioned itself for continued growth.

Despite recent weakness in the stock market, Regeneron's financials remain strong. According to Simply Wall St News, the company's financial performance is promising, making it an attractive choice for prospective shareholders. The company's stock, listed under the ticker symbol REGN, has shown resilience in the face of market challenges.

While we cannot provide specific investment advice, we recommend consulting with professionals from Stocks Prognosis for expert insights on the potential movement of Regeneron Pharmaceuticals' stock. Their expertise can help investors make informed decisions based on market trends and company performance.

Regeneron's commitment to scientific excellence and a patient-centric approach sets it apart in the pharmaceutical industry. With its upcoming earnings release and promising financials, the company continues to demonstrate its potential for success in the market.

Find out how the REGENERON PHARMACEUTICALS, INC. rate is expected to change

Get Forecast for REGN

Investor opinions & comments:

I'm not convinced that Regeneron's success will continue in the future. The pharmaceutical industry is highly competitive, and there are no guarantees
— from MadisonReyes at 01-11-2025 19:04
Regeneron's strong pipeline and successful partnerships make it an attractive choice for investors. I'm optimistic about its future prospects
— from OliverHayes at 01-11-2025 18:00
I'm confident in Regeneron's commitment to scientific excellence. Their patient-centric approach sets them apart from other pharmaceutical companies
— from SavingsSamantha at 01-11-2025 16:56
Regeneron's financial performance looks promising, which is reassuring for current shareholders. It's good to see the company's resilience in the face of market challenges
— from SaraBrown at 01-11-2025 05:06
I'm looking forward to the conference call and webcast to gain more insights into Regeneron's performance and future plans
— from MoneyMonique at 01-11-2025 02:23
I can't wait to hear more about Regeneron's pipeline of potential drugs. Their focus on innovation is impressive!
— from TraderTara at 01-09-2025 15:31
While Regeneron's financials may be strong, I'm concerned about the recent weakness in the stock market. It's important to consider the broader market conditions
— from LauraAnderson at 01-09-2025 12:12
I'm cautious about investing in biotechnology companies, as the industry can be volatile. It's crucial to carefully evaluate the risks involved
— from OliviaJackson at 01-09-2025 00:09
I'm excited to see Regeneron's financial and operating results for the fourth quarter and full year 2024. They have been making great progress in the pharmaceutical industry!
— from HannahCarter at 01-08-2025 19:06
If you want to leave a comment, then you need Login or Register





Other news for REGN

REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~2 min.

REGENERON PHARMACEUTICALS, INC. (REGN) has successfully reached the price target forecast set by QuantWave, resulting in a profit of 27.18%....

REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 26.25%  ~1 min.

REGENERON PHARMACEUTICALS, INC. stock recently achieved the price target forecast set by QuantWave on March 21, 2025. The forecast indicated a short direction, with the stock price at $657....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target Forecast, Bringing 27.31% Profit  ~1 min.

On March 4, 2025, QuantWave, the automated forecasting platform, issued a short signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at $674.49....

REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits 29.73% Profit Target as Forecasted by QuantWave  ~1 min.

REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) achieved a significant milestone as it hit the price target forecasted by QuantWave, providing investors with a profit of 29.73%....



Related news

REGNJanuary 2, 2025Regeneron Pharmaceuticals: An Impressive 89% Return Over the Last Five Years  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been a rewarding investment for shareholders, with a solid 89% return over the past five years, according to Yahoo Finance....

REGNJanuary 4, 2025Regeneron Pharmaceuticals Inc.: A Strong Investment Opportunity for Shareholders  ~1 min.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has proven to be a successful investment option for shareholders, with a decent 89% return over the last five years....

REGNJanuary 2, 2025Regeneron Pharmaceuticals: Discoveries and Innovations Driving Growth  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making significant strides in the pharmaceutical industry, driving growth and attracting investors....

REGNMarch 16, 2025JIM CRAMER ENCOURAGES INVESTORS TO OWN REGENERON PHARMACEUTICALS INC.  ~2 min.

In the latest episode of Mad Money, renowned financial expert Jim Cramer expressed his bullish stance on Regeneron Pharmaceuticals Inc. (REGN)....

REGNJanuary 1, 2025Regeneron Pharmaceuticals: A Promising Future for Investors  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has shown remarkable growth in recent years, with investors enjoying a decent 89% return over the last five years....